The influence of an additive treatment of orally administered AF with Salovum® was studied in patients suffering from severe acute onset of ulcerative colitis in a prospective, randomized, double-blind study. Patients were given 2 g of Salovum® four times daily for 14 days. A control group was given egg yolk powder without AF inducing ability.
A total of 20 patients, 10 in each group, fulfilled this study where this treatment was used as an additive to conventional medication, which also included parenteral or enteral nutrition.
Earlier trials performed in patients with chronic IBD, endocrine diarrhoea and diarrhoea due to intestinal resection showed varying, but significant effects on the number of bowel movements following induction of AF. The aim of this study was primarily to measure the histological effects on the intestinal epithelium. In addition other laboratory parameters of inflammation and clinical effect were studied.
During AF treatment, a reduction of inflammation in mucosal biopsies received from the mid-rectum was found. The secretory effect was not significantly different between groups. It was therefore concluded that the antisecretory effect of AF in ulcerative colitis is of importance only after the reduction of inflammation. The observation that AF treatment partially restored the intestine supports this hypothesis. It is likely that the antisecretory effect can be achieved by administering AF treatment in higher doses or through AF inducing cereals (SPC-Flakes®), triggering the endogenous production of AF protein.
Eriksson, Shafazand, Jennische and Lange, Effect of Antisecretory Factor in Ulcerative Colitis on Histological and Laborative Outcome: A short Period Clinical Trial, Scand J Gastroenterol, 2003; 10:1045-1049, view link